Phospho-CHK2 (Thr68) Rabbit anti-Human, Mouse, Invitrogen
Rabbit Recombinant Monoclonal Antibody
Manufacturer: Invitrogen MA527988
Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using Recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.Checkpoint kinase 2 (Chk2) is a serine/threonine-protein kinase which functions as a cell cycle checkpoint regulator. ATM and ATR kinases are activated in response to ionizing and ultraviolet radiation, and phosphorylate Thr68 and other sites in the amino-terminal region of Chk2 dimerization and activation. Activated Chk2 phosphorylates and inhibits Cdc25C phosphates, preventing the entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, Chk2 can phosphorylate BRCA1, allowing BRCA1 to restore survival after DNA damage. Chk2 is a putative tumor suppressor protein, with mutations in to the Chk2 gene linked to Li-Fraumeni syndrome, a familiar cancer usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors.
|PBS with 0.1% BSA, 50% glycerol and 0.02% sodium azide; pH 7.4|
|A synthetic phospho-peptide corresponding to residues surrounding Thr68 of human phospho Chk2|
|Control, Western Blot|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok